Loading
A phase 1/2 trial of Englumafusp alfa, Obinutuzumab, Glofitamab in non-hodgkin lymphoma, run by Hoffmann-La Roche, active and no longer recruiting.
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma is a phase 1/2 interventional study registered as NCT04077723 by Hoffmann-La Roche, with 498 participants planned, started 2019-08-13 and due to reach its primary completion in 2027-03-31. Interventions recorded: Englumafusp alfa, Obinutuzumab, Glofitamab, Tocilizumab. Conditions listed: Lymphoma, Non-Hodgkin. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Tocilizumab, Glofitamab, Obinutuzumab, Roche / Genentech.
Shares Tocilizumab, Glofitamab, Obinutuzumab, T-cell engagers (bispecific).
Shares Tocilizumab, Glofitamab, Obinutuzumab, T-cell engagers (bispecific).
Shares Glofitamab, Obinutuzumab, Roche / Genentech, T-cell engagers (bispecific).
Shares Tocilizumab, Roche / Genentech, T-cell engagers (bispecific), Non-Hodgkin lymphoma (all types).
Shares Tocilizumab, Glofitamab, T-cell engagers (bispecific), Monoclonal antibodies.
Shares Tocilizumab, Roche / Genentech, T-cell engagers (bispecific), Non-Hodgkin lymphoma (all types).
Shares Tocilizumab, Roche / Genentech, T-cell engagers (bispecific).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/